Timber Pharmaceuticals (TMBR +0.5%) receives a formal notice of allowance from the U.S. Patent and Trademark Office for the patent application covering its pharmaceutical tetracycline compositions for dermatological use.

Timber previously announced its intention to evaluate its proprietary topical programs, BPX-01 and BPX-04 and believes the expansion of claims for this patent will further protect these assets.

U.S. Patent Application No.: 16/514,459.


Source link